Muthukumaran Sivanandham

Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

Marc K. Wallack, Muthukumaran Sivanandham, Charles M. Balch et al. · Journal of the American College of Surgeons · 1998 · 179 citations

Medicine, Oncology, Surgery +16

A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma

Marc K. Wallack, Muthukumaran Sivanandham, Charles M. Balch et al. · Cancer · 1995 · 122 citations · Full text

Medicine, Immunology, Oncology +17

Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine

Marc K. Wallack, Muthukumaran Sivanandham, Kristen Ditaranto et al. · Annals of Surgery · 1997 · 48 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice

Muthukumaran Sivanandham, Palma M. Shaw, Stephanie F. Bernik et al. · Cancer Immunology Immunotherapy · 1998 · 24 citations · Full text

Life Sciences, Immunology, Oncology +17

Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model

Muthukumaran Sivanandham, Stephen D. Scoggin, Nobuyuki Tanaka et al. · Cancer Immunology Immunotherapy · 1994 · 21 citations · Full text

Medicine, Immunology, Oncology +16